
Peer reviewed version

License (if available):
CC BY-NC-ND

Link to published version (if available):
10.1016/j.jcmg.2018.06.003

Link to publication record in Explore Bristol Research
PDF-document

This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Elsevier at https://doi.org/10.1016/j.jcmg.2018.06.003. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Multi-Modality imaging in the assessment of cardiovascular toxicity in the cancer patient

Juan Carlos Plana, MD, Paaladinesh Thavendiranathan, MD, SM, Chiara Bucciarelli-Ducci, MD,PhD, Patrizio Lancellotti, MD

Juan Carlos Plana, MD
Chief, Cardiovascular Service line
Texas Heart Institute at Baylor St. Luke’s Medical Center
Houston, Texas, United States
Juan.plana@bcm.edu

Paaladinesh Thavendiranathan, MD, SM
Director, Ted Rogers Program in Cardiotoxicity Prevention
Peter Munk Cardiac Center
Toronto General Hospital, University Health Network
University of Toronto, Toronto, Canada
Dinesh.thavendiranathan@uhn.ca

Chiara Bucciarelli-Ducci, MD, PhD, FESC, FRCP
Bristol NIHR Biomedical Research Centre, Bristol Heart Institute, University of Bristol
Bristol, United Kingdom
C.Bucciarelli-Ducci@bristol.ac.uk

Patrizio Lancellotti, MD MD, PhD
University of Liège Hospital, GIGA Cardiovascular Sciences, Departments of Cardiology and Cardiovascular Surgery, Heart Valve Clinic, CHU Sart Tilman, Liège, Belgium, Gruppo Villa Maria Care and Research, Anthea Hospital, Bari, Italy

plancellotti@chu.ulg.ac.be

Address for Correspondence:

Juan Carlos Plana, MD

6620 Main Street, Suite 11A.14, BCM 620

Houston, Texas 77030
Abstract

Cancer therapy can be associated with both cardiac and vascular toxicity. Advanced multi-modality imaging can be used to risk stratify patients, identify cardiovascular injury during and after therapy, and prognosticate recovery. Echocardiography continues to be the mainstay in the evaluation of cardiac toxicity. In particular, echocardiography based strain imaging is useful for risk stratification of patients at baseline and detection of sub-clinical LV dysfunction during therapy. Cardiac magnetic resonance (CMR) serves a complementary role in the patient with poor echocardiography or ERNA image quality or in situations where a more accurate and precise LVEF measurement is needed to inform decisions regarding chemotherapy discontinuation. New CMR techniques like T1 and T2 mapping as well as PET imaging will help us better understand the structural, pathological, and metabolic myocardial changes that are associated with ventricular dysfunction or release of serum biomarkers. CMR may also be helpful in the evaluation of the vascular complications of cancer therapy. Stress echocardiography, stress CMR, CT and PET are excellent imaging options in the evaluation of ischemia in patients receiving therapies that could potentially cause vasospasm or accelerated atherosclerosis.
Abbreviations

CAD = coronary artery disease
CMR = cardiac magnetic resonance
CTRCD = chemotherapy-related cardiac dysfunction
EDV = end-diastolic volume
ERNA = equilibrium radionuclide angiography
ESV = end-systolic volume
GLS = global longitudinal strain
GCS = global circumferential strain
GRS = global radial strain
HER2+ = human epidermal growth factor receptor 2 positive
TKIs = tyrosine kinase inhibitors
VEGFi = vascular endothelial growth factor inhibitors
Introduction

The field of oncology has advanced remarkably. In some instances, cancer is either cured or converted into a chronic disease. Nevertheless, some of the old and new emerging cancer therapies are associated with the development of cardiovascular toxicities (1,2), which may have the potential to offset the gains in survival obtained with these cancer breakthroughs.(3) Much of the focus on cardiovascular toxicities has been in the early detection of myocardial damage and the prediction of cancer therapeutics related cardiac dysfunction (CTRCD). However, since the toxicities associated with cancer therapies are much broader (Table # 1)(4), in this manuscript, we review how advanced multi-modality imaging can be used to risk stratify patients before starting cancer therapy, identify early cardiovascular injury during therapy, predict recovery from it, and detect cardiovascular injury in long term cancer survivors.

Clinical case

A 51year-old female with left sided, high risk, early stage HER2+ breast cancer was referred to the cardio-oncology clinic. Her treatment plan included mastectomy, epirubicin 300mg/m², 17 cycles of trastuzumab, radiation therapy (50Gy), and hormonal therapy. She had no known cardiovascular risk factors, was not receiving medications, and had excellent functional capacity. Imaging and biomarker assessments were performed prior to cancer therapy, throughout her treatment and one year later (Table 2). Her baseline blood pressure was 138/80, cardiac examination was unremarkable, her LVEF by 3D echocardiography was 61%, the global longitudinal strain (GLS) was -21.3%, and the global circumferential strain (GCS) was -20.3%. Several questions were raised during her initial consultation and follow up: How does cardiac imaging play a role in identifying cardiovascular toxicity risk in this patient? What is the best
method to detect early cardiac injury from treatment? What are the predictors of ventricular function recovery after cardiotoxicity?

Assessment of baseline risk of cardiovascular complications in patients receiving cancer therapy

Assessing risk of CTRCD / heart failure

The American Society of Clinical Oncology guidelines recommend risk stratification for cardiac dysfunction prior to initiation of potentially cardio-toxic cancer treatment. We refer the readers to their discussion of which patients with cancer are at increased risk of developing cardiac dysfunction.(5) From the imaging standpoint, patients with borderline cardiac function (left ventricular ejection fraction (LVEF) 50-55%, history of myocardial infarction, and presence of other cardiac comorbidities (e.g. ≥ moderate valvular heart disease)) before the start of anthracycline or trastuzumab therapy are at an increased risk (3.6- to 11.8-fold) for developing cardiac dysfunction(5). The expert consensus for the multi-modality imaging evaluation of the adult patient during and after cancer therapy recommends a baseline echocardiogram, with the calculation of LVEF ideally using three dimensional echocardiography and global longitudinal strain (GLS) if the technology is available and the operators are comfortable with their performance and interpretation.(6) The latter is a reflection of the superior reproducibility of 3D LVEF and GLS measurements.(7,8) In addition to LVEF, pre-treatment measurements of GLS appear to identify patients at elevated risk of MACE in the context of anthracycline therapy.(9,10) Similarly every 1% difference in baseline circumferential strain has been associated with a 31% increased odds of cardiotoxicity in women receiving breast cancer therapy.(11)
Cardiac magnetic resonance (CMR) is usually not used as a first-line tool for risk stratification due to its cost and lack of wide availability. However, in patients with a non-diagnostic echocardiogram, unexplained dilation of the left or right ventricles, or morphological abnormalities raising concern for an infiltrative cardiomyopathy, CMR can complement the echocardiographic evaluation to assess for a potential etiology. To date, however, there is no data as to whether pre-treatment CMR parameters identify patients at risk for cardiotoxicity.

**Coronary artery disease risk**

Stress echocardiography may be useful in the evaluation of patients with intermediate or high probability of CAD, who are undergoing regimens that may be associated with ischemia (e.g. 5-fluoracil, bevacizumab, sorafenib and sunitinib).(6) Cardiac computed tomography (CCT) has changed the landscape of coronary assessment in the field of cardiology. Its role in Cardio-oncology is primarily restricted to assessment of coronary calcium and obstructive coronary artery disease.(12). Nuclear and PET stress testing both represent alternatives for the evaluation of CAD in these patients. Stress CMR can detect the presence and extent of inducible myocardial ischemia with high diagnostic accuracy.(13) The attraction of stress echocardiography and stress CMR is the lack of radiation exposure. However, stress echocardiography may be challenging in patients who have had mastectomies, breast expanders or implants. In these situations, the use of ultrasonic enhancing agents may improve visualization of the myocardial segments and accuracy of interpretation.(14) CMR may be not feasible in the presence of certain breast tissue expanders due to their ferromagnetic components.(6)

**Vascular toxicity**
Many agents used in cancer treatment such as tyrosine kinase inhibitors (TKIs), vascular endothelial growth factor inhibitors (VEGFi), antimetabolites, and radiation therapy are associated with direct vascular toxicity while hormonal therapy can increase the risk of atherosclerotic vascular events.\(^{(15, 16)}\) Potential vascular toxicities include, hypertension, coronary artery disease, peripheral arterial disease, pulmonary hypertension, and venous thrombosis.\(^{(16)}\) Although certain clinical risk factors for these toxicities have been described (e.g. pre-existing hypertension), unlike cardiomyopathy, there has been no literature examining vascular imaging parameters to identify patients at risk.\(^{(16)}\) The area of vascular risk in cancer survivors however has gained significant attention with the description of Clonal Hematopoiesis (CH) as a risk factor for atherosclerotic vascular disease.\(^{(17)}\) CH is an expansion of myeloid and lymphoid cells that carry recurrent somatic mutations. CH appears to be identified in approximately 10% of patients aged 70-79\(^{(18)}\) with a 4 fold increased incidence in patients receiving cancer therapy compared to untreated patients.\(^{(19)}\) Patients with CH are at a 2.0-2.6 fold higher risk of coronary or cerebrovascular disease.\(^{(20)}\) Therefore, identifying patients with CH and performing targeted vascular imaging may be a novel future approach to risk stratification.

**Early identification of cardiovascular injury during cancer therapy**

*Early detection of CTRCD*

**Evaluation of LV volumes and function**

Historically, planar equilibrium radionuclide angiocardiography (ERNA) and SPECT-ERNA provided reliable and accurate means of calculation of LVEF. However, although extensive literature exists in the cancer setting, these techniques are almost abandoned due to the concern
of radiation exposure, especially during repeated examinations. In addition, modern multiple gated acquisitions scans (MUGA) may not allow optimal patient positioning for LVEF assessments.(6) The limits of agreement between MUGA and CMR for LVEF are wide (−19.4 to 16.5%). At LVEF threshold of 50%, the cut-off defining cardiac toxicity, there is a risk of misclassification of 35% of cancer patients.(21) It is also important to note the additional limitation of ERNA due to its inability to evaluate right ventricular or valvular function, and pericardial disease.

Although CCT has the capability of providing a measurement of LV volumes and LVEF, it comes at the cost of radiation exposure. Therefore, CCT does not have a routine role in the surveillance of cardiac function or vascular toxicity during cardio-toxic cancer therapy. Surveillance and detection of CTRCD is currently performed using echo derived LVEF, and more recently strain imaging.(6) The overall goals are: 1) the correct adjudication of Stage B heart failure, so that modern heart failure therapy could be initiated, 2) the accurate calculation of LV volumes in the assessment of LV remodeling; and 3) the potential identification of situations where changes in loading conditions may be playing a role in changes in LVEF or strain.

The best method to measure LVEF to identify early cardiovascular injury is unclear. CMR can identify small changes in LVEF that appear to parallel the changes in myocardial strain.(22) However, whether such small early changes predict subsequent CTRCD or are just the result of hemodynamic variability is unclear.(23) CMR may be useful clinically in situations where there is concern regarding echocardiographic or equilibrium radionuclide angiography
(ERNA) calculation of LVEF or in situations where a more accurate and precise LVEF measurement is needed to inform decisions regarding chemotherapy discontinuation.(6) Interestingly recent work in women receiving therapy for breast cancer has suggested that nadir LVEF values are identified by 3D echocardiography earlier than 2D echocardiography suggesting that 3DE measured LVEF may be a useful method to identify early cardiac injury.(24) For adjudication of Stage B heart failure during cancer therapy, based on a single study, 3D LVEF appears to identify more patients who meet CTRCD criteria than 2D LVEF.(25). Accurate calculation of LVEF should be done with the best method available in the echocardiography laboratory (ideally 3D echocardiography).(6) It is important to recognize that although ideal, the technique or the expertise in its interpretation may not be widely available outside academic centers. In such scenarios, ultrasound enhancing agents should be used to enhance 2D echocardiography when two contiguous LV segments are not well visualized on non-contrast apical images.(6) The obtained LV volumes will be larger with closer correlation with CMR. The recently published clinical applications of ultrasonic enhancing agents in echocardiography reported a study examining baseline pre-chemotherapy echocardiograms in female patients where 51% of contrast enhanced diastolic volumes were classified as abnormal, despite the LV dimensions being within the normal range by unenhanced 2D volume measurements. To account for this change in normal range the document proposed an end diastolic volume upper limit cutoff of 83 ml/m2 for women and 98 ml/m2 for males.(26) Armstrong et al compared LV volumes measured with 2D and 3D echocardiography against CMR. They found that although the 3D calculated LVEDV and LVESV were closer to the ones calculated by CMR, there was still underestimation (mean EDV 12cc, mean ESV 5cc, p<0.001 for both).(27)
Left ventricular volumes and ejection fraction are not fixed for a given individual. They fluctuate reflecting dynamic changes in loading conditions and inotropic state. A reduction in LVEF can be due to either an increase in LVESV or reduction in LVEDV. In patients treated with anthracycline and/or trastuzumab, the primary driver for a reduction in LVEF is an increase in LVESV. (22,28-30) Patients may exhibit potential reductions in LVEDV caused by intravascular volume depletion (reduced preload) from cancer therapy related poor oral intake, vomiting or diarrhea. Two recent studies of patients with various cancers receiving chemotherapy demonstrated that 16-19% of patients who met criteria for CTRCD only had an isolated reduction in LVEDV without a “significant” increase in LVESV. (23,31) This has important implications for clinical management of sub-clinical LV dysfunction and CTRCD, and is a cause for pause and further investigation. However, several concepts should be considered when interpreting this data. First, up to 6% variability in LVEF and 21ml in LVEDV can occur with CMR measurements due to variability in contouring the basal short axis slice. This is particularly important in longitudinal studies where even the acquisition of the basal slice could be different due to variability in image setup. (32,33) Secondly, based on cardiac physiology, a reduction in LVEDV does not occur in isolation. It is associated with a sympathetic reflex that increases inotropy, which in turn will increase the slope of the end-systolic-pressure volume relationship. In addition the reduction in stroke volume results in reduced systemic pressure with subsequent reduction in afterload. In combination the LVESV also decreases. This concept is supported by recent work where healthy individuals subjected to 2.0-3.5% intravascular volume depletion had a reduction in both LVEDV and LVESV without a statistically significant reduction in LVEF or circumferential strain. (34) Therefore the lack of a reduction in LVESV associated with a
reduction in LVEDV seen in these recent studies suggests a concomitant reduction in myocardial contractility to explain the reduction in LVEF. Finally it is important to recognize without making CMR the technique to routinely follow patients during cancer therapy, that our echocardiography techniques do not have the ability to identify small changes in ventricular volumes during cancer therapy.(8) Hence using ventricular volumes as surrogates of intravascular status would not be practical in routine clinical practice.

The findings of potential volume dependency of LVEF measurements further emphasize the importance of repeating cardiac imaging 2-3 weeks later upon discovery of sub-clinical LV dysfunction or CTRCD before consideration of changes to cancer therapy or initiation of cardiac medications.(6) It is also important to perform the surveillance imaging at times when patients are less likely to be intra-vascular volume depleted, such as the day before the next chemotherapy cycle.

**Evaluation of LV deformation: strain imaging.**

Negishi et al found that the strongest predictor of CTRCD was delta 2D-based GLS during treatment. An 11% reduction (95% confidence interval, 8.3 to 14.6%) half way through trastuzumab therapy was the optimal cutoff with a sensitivity of 65% and a specificity of 94% for subsequent cardiotoxicity. GLS was an independent early predictor of later reductions in LVEF, incremental to usual predictors in patients at risk for trastuzumab-induced cardiotoxicity. Their findings served as the scaffolding for the subsequently published expert consensus that recommends the use of global longitudinal strain for the surveillance of subclinical LV dysfunction for patients being treated with anthracyclines or trastuzumab with a reduction of >15% compared to baseline illustrating a clinically significant change.(6) Nevertheless, the
association between GLS and subsequent CTRCD may have been potentially misinterpreted postulating that 1) GLS falls before LVEF in patients receiving cardio-toxic therapies and 2) there is a compensatory increase in global circumferential strain (GCS) in response to the reduction in GLS in order to initially preserve LVEF. The recently study published by Stokke et al can help us understand the relationship between LVEF and its determinants: GCS, GLS, LV internal dimension and wall thickness. The model showed that GCS contributes more than twice as much to LVEF when compared with GLS. For the LVEF to be maintained, a reduction of GLS needs to be compensated by an increase in GCS or wall thickness or reduced LV diameter.

In the above mentioned study by Negishi et al, LVEF, GLS and GCS decreased in parallel from baseline to 12 months from 58±5.5% to 55±5.3%, from -20.7% to -18.3%, and from -17.8% to -15.9% respectively. GRS decreased from 50.9% to 45.7%.(35) Other studies have also demonstrated simultaneous reduction in all these parameters.(11,36)

The 6-month data from Negishi et al’s study can help us understand the limitations of using 2D-echocardiography and the role of 2D based strain for the early detection of sub-clinical LV dysfunction. The LVEF decreased from 64±4.6% to 58±5.5% (6 absolute point reduction in LVEF), which is below the 10 point threshold ability of 2D based echocardiography to discriminate sequential changes in LVEF.(8) At 12 month follow up, the LVEF continued to deteriorate being reported at 55± 5.3% (9 absolute point reduction in LVEF), very close to the threshold giving the reader the ability to recognize the change. In parallel, there was a reduction in GLS from -20.7±2.6% to -18.3±2.1% at 6 months (2.4 absolute reduction, 11.6% relative reduction when compared to baseline), which remained unchanged at 12 months. The lower intra and inter-observer variability of GLS allows easier recognition of the change in systolic function
when compared to LVEF. The relative mean error for GLS is 1.7 (below the 2.4 change noted during surveillance) making 2D based strain well suited for the identification of sub-clinical LV dysfunction.(37)

Using CMR, Drafts et al initially reported on the behavior of LVEF and GCS 1,3 and 6 months in 53 patients receiving low-dose anthracyclines (50-375 mg/m²) for the treatment of breast cancer, leukemia and lymphoma. LVEF and GCS decreased from baseline to 6 months 58 ± 1% to 53 ± 1% (p=0.0002) and from -17.7% ± 0.4% to -15.1 ± 0.4, (p=0.0003) respectively.(22)

In 101 patients receiving cardio-toxic agents in the setting of various malignancies, Jordan et al subsequently published data incorporating CMR mid-wall eulerian GCS, including this time GLS (n=34, using high-temporal-resolution 2- and 4-chamber cine views), and LVEF.(31)

Overall GLS declined from -15.44 to -14.79 (p=0.069), GCS from -17.99 to -17.23% (p=0.0052) and LVEF from 59.2 to 56.7% (p= 0.0002).

LV mass was unchanged by MRI in the patients who developed CTRCD. The diameter of the ventricle increased only slightly during and after anthracycline therapy.(22)

The data from these echo and CMR studies suggest that the reduction in LVEF may be explained by the parallel reduction in GLS and GCS with slight contribution from the increase in LV internal dimension. The apparent misconception that GLS changes before LVEF appears to be explained by the inability of 2D based echocardiography to recognize changes <10 %.

Larger studies ideally using MRI based LVEF and strain are needed to further study this concept.

The significant interest in tri-plane and 3D speckle tracking is currently limited by the poor correlation of values of this technique when compared with 2D based strain. There are two
explanations: the limited feasibility due to poor tracking of the segments and the differences in acquisition rates (low volumes per second when compared to the high frame rates attainable with its 2D counterpart). We are hopeful that technology will evolve over time overcoming these challenges.(38)

**Tissue characterization**

CMR may facilitate our understanding of the pathogenesis of CTRCD. Myocardial tissue changes such as intracellular and interstitial edema and fibrosis may precede the alterations in LV volumes, reduction in LVEF, or changes in myocardial strain and may represent early markers of myocardial injury. Multiple CMR imaging sequences such as T1 and T2 weighted imaging, as well as newer T2 and T1 mapping sequences can help identify intracellular and interstitial edema and are now part of our armamentarium (Figure 1).(39,40) Native T1 mapping or a combination of pre and post contrast T1 mapping can be used to calculate extracellular volume fraction (ECV) as a marker of edema or interstitial fibrosis.(41) Post-contrast T1 weighted imaging (late gadolinium enhancement, LGE) can be used to identify myocardial replacement fibrosis

Several small studies using CMR have shown myocardial edema early following anthracycline therapy using T2 weighted sequences.(30,42) The presence of edema has been associated with persistent reduction in RV function in follow-up. (30) CMR studies have also demonstrated presence of focal and replacement fibrosis with variable patterns (epicardial, mid-wall, insertion points) and incidence. Nevertheless this finding has not been consistent in the literature.(40) Also, there is accumulating evidence of the presence of diffuse interstitial fibrosis measured by
native T1 mapping and ECV in anthracycline-induced cardiomyopathy. It manifests independent of the presence of cardiovascular comorbidities and is associated with impaired diastolic function.\(\text{(43,44)}\) In cancer survivors, an increase in ECV has been associated with higher anthracycline doses and lower exercise capacity.\(\text{(45)}\) In this latter cohort the increase in ECV is likely a marker of interstitial fibrosis.

Some CMR studies have described subepicardial LGE of the lateral wall in patients with trastuzumab cardiomyopathy, suggesting an underlying myocarditis, however, this has not been reproduced in other studies. \(\text{(46,47)}\) Whilst the presence of LGE has been associated with prognosis in a range of ischemic and non-ischemic cardiomyopathies, there is no similar data in patients with CTRCD.\(\text{(48)}\) However, LGE imaging may have value in evaluation of patients receiving cancer immunotherapy with a clinical suspicion for myocarditis. Cardiotoxicity related to immunotherapy includes heart failure, Takotsubo-Like syndrome and fulminant myocarditis with fatal outcome\(\text{(49)}\). CMR is known to be a valuable modality for detection of myocarditis using the Lake Louise Criteria.\(\text{(50)}\) Although this has not been formally evaluated in the setting of immune therapy, a recent case series of 35 patients with immune therapy mediated myocarditis identified LGE in a mid-myocardial, sub-epicardial or diffuse pattern in 77\% of the patients (Figure 2).\(\text{(51)}\)

**Myocardial metabolism**

PET imaging provides a unique assessment of myocardial metabolism, which may identify the earliest myocardial or vascular changes related to toxicity. Although changes in FDG uptake
appear to identify patients at risk of doxorubicin mediated cardiotoxicity (52), the use of PET imaging to identify early cardio-toxicity is still limited to the research realm.

**Complementary role of biomarkers.**

Several biomarkers have been proposed for early detection of CTRCD, the most studied ones are troponin, resulting from cardiomyocyte damage and natriuretic peptides reflecting elevation in left ventricular filling pressure and wall stress. Troponin is recognized as a highly efficient predictor of early and long-term cardiac toxicity. Cardinale et al had previously demonstrated that Tn I positivity, soon after anthracycline containing regimens is a strong predictor of LVEF reduction and poor cardiac outcome, particularly in patients showing persistent (> 1 month) troponin positivity.(53-55) Her group also showed that in trastuzumab treated patients, TNI evaluation provides an opportunity to recognize patients at risk of developing trastuzumab induced CTRCD and among them, those who are less likely to recover from it despite optimal heart failure therapy.(56) There is debate regarding the clinical usefulness of the measurement of natriuretic peptides because of discordant results (1,2). Noteworthy, data on the complementary role of biomarkers to imaging in cancer patients are yet limited but encouraging. Sawaya et al. showed a negative predictive value of 91% when a decrease in GLS (<19%) was combined with an elevation of ultrasensitive TnI in breast cancer patients receiving doxorubicin and trastuzumab.(57) Similarly, the combination of elevated TnI and MPO levels was shown to identify a group of patients with breast cancer at increased risk for cardiotoxicity than each individual biomarker alone.(58) A combined multimodality imaging / biomarker approach in selected individuals may thus be of interest for risk prediction and to guide therapy.
**Detection of pulmonary hypertension**

Pulmonary hypertension can occur during cancer treatment due to venous thromboembolism, compression by the tumor, or due to use of tyrosine kinase inhibitors such as dasatinib. Echocardiography remains the primary method to screen for pulmonary hypertension during treatment via the measurement of right ventricular systolic pressure from the tricuspid regurgitation jet.

**Vascular toxicity**

There has been growing interest in expanding our understanding of the effects of cancer therapeutics in the cardiovascular system beyond the heart. Arterial stiffness by pulse wave velocity (PWV) can identify vascular changes in the asymptomatic sub-clinical stage: vascular ultrasound can assess both the local and carotid-femoral arterial stiffness, whilst MRI can assess both the local and the central arterial stiffness. Di et al have recently reviewed cancer therapy therapy-induced vascular toxicity. (59) Useful imaging biomarkers in this context are the non-invasive flow-mediated dilation (flow hyperemic mediated dilation) of the brachial artery to detect endothelial dysfunction and increased intima-media thickness of the common carotid artery measured by ultrasound. Using CMR, thoracic aortic pulse wave velocity (PWV), a marker of vascular stiffness, appears to increase steadily after the administration of anthracyclines. While adjusting for baseline heart rate had minimal impact on the change in velocity over time, participants with a higher systolic blood pressure had a higher pulse wave velocity at rest and a faster increase in PWV, highlighting the interaction between the effects of the chemotherapeutic agents and the baseline risk factors of the patient. Aortic distensibility can also be assessed by gated computed tomography but both the radiation burden and lower
temporal resolution (which may lead to underestimation of distensibility) limit its use in this context. (60) Despite these interesting findings, whether these early changes result in subsequent symptomatic vascular disease remains unknown.

**Prediction of recovery of cardiovascular toxicity**

*CTRCD*

Once there is a reduction in myocardial function identified during cancer therapy, there is very little data on predictors of recovery other than the timing of heart failure therapy initiation. (61) In patients receiving sequential anthracycline and trastuzumab based therapy nadir GLS value greater than -15.8% may identify patients at higher risk of lack of LVEF recovery (HR 0.39, 95% CI 0.18-0.74). (62) Similarly in anthracycline treated patients, lower LVEF at initiation of HF treatment may be associated with lack of recovery of ventricular function. (63) The only other imaging predictors of ventricular function recovery is larger left atrial volume (OR 0.94, 95% CI 0.88-0.99). (64) These parameters together suggest that those who have more severe myocardial dysfunction as measured by EF, strain, or atrial remodeling at initiation of HF therapy are less likely to have recovery of heart function.

**Detection of cardiovascular disease in long-term cancer survivors**

*Detection of CTRCD*

The high risk for adult onset CTRCD after treatment for childhood and adolescent neoplasia warrants early detection when intervention is expected to be of greater benefit. The Children’s Oncology group long-term follow up guidelines recommend periodic evaluation by echocardiography. Traditionally, the measurement has been obtained using two-dimensional
echocardiography. In cancer survivors, compared with CMR, the sensitivity and false-negative rate improve from 25% and 75% to 53% and 47% respectively when using 3D echocardiography instead of 2D echocardiography, reducing the misclassification rate of Stage B heart failure patients as normal from 11% to 5%. (27) However, in a larger cohort of 1820 adult survivors of childhood cancer, while only 5.8% of the patients had abnormal 3D LVEFs (< 50%), 32.1% of survivors with normal 3D LVEF had cardiac dysfunction by GLS (28%), by diastolic assessment (8.7%), or both. Abnormal GLS was associated with the dose of chest radiation and anthracyclines based chemotherapy received. Interestingly, survivors with the metabolic syndrome were twice as likely to have abnormal GLS or diastolic dysfunction. They concluded that the use of modern echocardiography may allow identification of a subset of survivors who may benefit from early medical intervention. (65)

CMR based extracellular volume fraction (ECV) has been examined as a measure of subclinical cardiac injury in both pediatric and adult cancer survivors. In pediatric cancer survivors ECV appears to be associated with total anthracycline dose, markers of adverse ventricular remodeling, and lower VO2 max. (45) In anthracycline treated adults ECV fraction is increased in cancer survivors compared to controls, with higher values in those with reduced versus preserved LVEF. (44) Elevated ECV is also correlated with measures of worse diastolic dysfunction such as higher lateral annular E’ velocity and E/e’ ratio. Compared to matched controls and a separate cohort of patients imaged prior to cancer therapy, ECV values appear to be elevated particularly in those receiving anthracycline based therapy. (43) These data suggest that increased ECV may occur in cancer survivors with preserved or reduced LVEF and that it identifies a cohort of patients with potentially vulnerable myocardium. Whether these
abnormalities have future implications for the cardiovascular health of patients remains to be determined.

In addition to LV dysfunction recent studies of lymphoma survivors have also described right ventricular (RV) systolic dysfunction. The association between LV function (LV global longitudinal strain) and RV function (tricuspid annular plane systolic excursion), indicated a global long-term cardiotoxic effect. However, RV dysfunction (6.2%) was less prevalent than LV dysfunction (30.8%) (p<0.001).(66,67)

**Detection of pericardial disease**

Pericardial disease can be seen as a long term consequence of radiation therapy to the chest. Echocardiography remains the primary modality to screen for pericardial constriction in patients with suggestive symptoms.(68) Cardiac CT can help assess the presence and extent of pericardial calcification (Figure 3). In patients in whom echocardiography is not diagnostic, cardiac MRI also provides an assessment of the presence of pericardial thickening, its extent, as well an assessment of the constrictive physiology (Figure 3).(68)

**Detection of vascular toxicity**

Radiation-induced cardiovascular disease appears to be associated with damage to endothelial cells via transient increases in oxidative stress, impaired vascular wall homeostasis, endothelial dysfunction and apoptosis of endothelial cells, subsequent inflammatory response leading to increased expression of matrix metalloproteinases, adhesion molecules, and proinflammatory cytokines and downregulation of vasculoprotective nitric oxide, leading to accelerated
atherosclerosis, increased blood viscosity and unstable platelet aggregates\(^{(69)}\). Arterial stiffness is a precursor of atherosclerosis and is increased in irradiated arteries, in keeping with radiation-induced damage. Early and late changes in markers of aortic stiffness with breast cancer therapy was measured with CMR at baseline, 1, 4 and 14 months post-therapy measuring aortic pulse wave velocity (PWV) and distensibility at ascending aorta and proximal descending aorta. They demonstrated that acute changes are observed in PWV and distensibility at the ascending aorta following contemporary breast cancer chemotherapy and partially reverse a year after therapy is discontinued, with more severe effects seen with anthracyclines\(^{(70)}\). Childhood cancer survivors show a reduced vascular health\(^{(71)}\) and increase in arterial stiffness was also demonstrated in following chemotherapy\(^{(72)}\). The long-term effects of radiotherapy on arterial stiffness can be involved in increasing cardiovascular risk in breast cancer-treated women\(^{(73)}\).

The assessment of coronary calcium and obstructive coronary artery disease can be achieved robustly using cardiac computed tomography (CCT)(Figure 4) and stress CMR (Figure #5). In survivors, a coronary calcium score may help with risk stratification and guide intensity of risk factor modification.

**Discussion about the patient**

Our patient had no traditional cardiovascular risk factors. Although her baseline 3D LVEF and GLS were normal, her GCS was mildly reduced which may be a pre-treatment risk of CTRCD (Table 2).\(^{(11)}\) She has a reduction in 3D LVEF immediately post anthracycline but not meeting CTRCD criteria. However, she had >15% relative reduction in GLS meeting criteria for subclinical LV dysfunction\(^{(6)}\). Given the absence of convincing data for intervention with isolated reduction in GLS, no cardiac therapy was instituted. She presented 1 month later with
stage C HF. Her lowest GLS was measured at 15.1% suggesting that there is a reduced chance of completed LVEF recovery. (62) With 2 trastuzumab cycles held and initiation of beta-blockers and ACE inhibitors, her LVEF and GLS improved, however, despite ~2 years of cardiac medications her GLS and LVEF remains mildly reduced.

**Outcomes in Cardio-Oncology and Future directions.**

The goal for the cancer patient is to fully administer the prescribed regimen with no interruptions, aiming at cure or remission, with a survival free of cardiovascular morbidity and mortality. This brings us to the question as to the optimal outcome to follow in Cardio-oncology?

We propose to strengthen the partnership between imaging, oncology and heart failure specialists and very importantly, the cancer patient so as a group we can come to an agreement as to the outcomes we believe will matter, so we can use them effectively to understand and mitigate the cardiovascular toxicity of old and new agents. We anticipate that the oncologists will include the ability to deliver full and uninterrupted regimens. We the imagers, would like to include LV volumes, LVEF and mass and deformation indices. Our heart failure colleagues will obviously be interested in the accurate adjudication of cardiomyopathy, heart failure and cardiovascular mortality as well as the use of biomarkers (troponin, BNP and NT-BNP) and tests evaluating functional exercise capacity (6 minute walk test and VO2 max). The patient would likely add quality of life to the above-mentioned metrics.

Regardless of our field of expertise, we have one shared goal: cancer survival without cardiovascular disease. We look forward to continuing the advancement of the field of
multimodality imaging with the hope achieving this goal through the demonstration of impact on outcomes.

**Acknowledgements:** Dr. Thavendiranathan is supported by the Canadian Institutes of Health Research New Investigator Award (FRN 147814). We like to acknowledge the support of Dr. Elena Milano and Dr. Iwan Harries generating Figure #1 and #5 respectively. Dr Bucciarelli-Ducci is supported by the Bristol National Institute of Health Research (NIHR) Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the National Health Service, National Institute for Health Research or Department of Health, United Kingdom.

**Disclosures**

CBD is a consultant for Circle Cardiovascular Imaging (Calgary, Canada).
References

13. Authors/Task Force m, Windecker S, Kolh P et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of


Figure Legends

Figure 1: CMR tools to understand the underlying mechanisms of cardiotoxicity. (Panels A and B) Cardiac MRI studies in a patient during and after 6-month withdrawal of trastuzumab: end-diastolic (EDV) frame, end-systolic (ESV) frame, feature tracking analysis and curves and native T1 mapping. At 6-month withdrawal, both EDV and ESV are reduced, ejection fraction increased, longitudinal strain improved, and native T1 values were reduced. This case demonstrated the reversible nature of trastuzumab cardiomyopathy. (Panel C) CMR study in a patient with anthracycline-cardiomyopathy, with reduced EDV and ESV, reduced ejection, impaired global longitudinal strain, and presence of subepicardial and mid-wall late gadolinium enhancement (LGE) in the septum, inferior and inferolateral walls.

Figure 2: Myocarditis identified by cardiac MRI. Panel A demonstrates a focal area of myocardial edema on spectral attenuated inversion recovery (SPAIR) image (arrow) while panel B demonstrated sub-epicardial enhancement (arrow) on late gadolinium enhancement images reflective of myocardial cell death. The sub-epicardial enhancement is a pattern often seen in myocarditis.

Figure 3: Assessment of pericardial constriction using cardiac MRI. Panel A demonstrates a T1 weighted spin echo sequence demonstrating thickening of the pericardium (arrow). Panel B and C demonstrate a real time cine sequence with normal position of the interventricular septum in expiration (Panel B), but shift into the LV during inspiration (Panel C). This finding of respirophasic septal shift is a hemodynamic feature of constrictive physiology.
**Figure 4:** Cardiac computed tomography for assessment of coronary artery disease. In patients with prior chest radiation Panel A demonstrates pericardial calcification, panel B significant proximal coronary artery disease involving the left anterior descending. Panel C demonstrates mixed plaque in proximal LAD in a patient experience chest pain during treatment with 5-fluorouracil.

**Figure 5:** Significant peri-infarct ischemia (panel A, white arrow) in the basal to mid-cavity of the anterior wall (LAD territory) in a 57 year old male with a prior history of chemotherapy and radiation for small cell lung cancer.

Panel A: Basal, mid, apical short-axis slice first pass perfusion images using a GRE sequence after adenosine infusion and administration of 0.1 mmol/kg of gadolinium chelate contrast agent.

Panel B: corresponding basal, mid, apical short-axis late gadolinium enhancement images using a IR-GRE sequence 15-20min after contrast administration.
Table 1: Cardiovascular toxicities where Imaging plays a role in risk stratification, detection or prognosis

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Agents</th>
<th>Imaging recommended</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTRCD / Myocarditis</td>
<td>Anthracyclines, Alkylating agents, Antimetabolites, Antimicrotubule agents, Monoclonal antibody based tyrosine kinase inhibitors, Proteasome inhibitors, Small molecule tyrosine kinase inhibitors, Immune therapy</td>
<td>3D Echo (ideally) / 2D Echo GLS CMR</td>
</tr>
<tr>
<td>Valvular heart disease</td>
<td>Radiation induced heart disease</td>
<td>2D Echo CMR</td>
</tr>
<tr>
<td>Pericardial disease</td>
<td>Methotrexate, Arsenic trioxide, Antimetabolites, Antimicrotubule agents, Radiation therapy</td>
<td>2D Echo CT CMR</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>Antimetabolites, Antimicrotubule agents, Monoclonal antibody based</td>
<td>Stress echocardiography CCT Stress CMR</td>
</tr>
<tr>
<td>Condition</td>
<td>Treatment</td>
<td>Imaging Modality</td>
</tr>
<tr>
<td>--------------------</td>
<td>----------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>tyrosine-kinase inhibitors</td>
<td>PET</td>
<td></td>
</tr>
<tr>
<td>Small molecule tyrosine kinase inhibitors</td>
<td>2D Echo</td>
<td></td>
</tr>
<tr>
<td>Pulmonary hypertension</td>
<td>Small molecule tyrosine kinase inhibitors</td>
<td>Vascular ultrasound</td>
</tr>
<tr>
<td>Vascular toxicity</td>
<td>Anthracyclines</td>
<td>CMR</td>
</tr>
</tbody>
</table>
Table 2: Temporal changes in cardiac function, biomarkers, and symptoms in the clinical case presented.

<table>
<thead>
<tr>
<th>Time</th>
<th>3D EF</th>
<th>2D EF</th>
<th>GLS</th>
<th>HsTpI</th>
<th>NYHA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre cancer therapy</td>
<td>61</td>
<td>64</td>
<td>-21.5</td>
<td>2</td>
<td>I</td>
</tr>
<tr>
<td>Post anthracycline</td>
<td>53</td>
<td>55</td>
<td>-17.9</td>
<td>48</td>
<td>I</td>
</tr>
<tr>
<td>1 month into Herceptin</td>
<td>48</td>
<td>47</td>
<td>-15.1</td>
<td>102</td>
<td>II-III</td>
</tr>
<tr>
<td>6 weeks</td>
<td>56</td>
<td>60</td>
<td>-19.2</td>
<td>17</td>
<td>I</td>
</tr>
<tr>
<td>6 months</td>
<td>53</td>
<td>54</td>
<td>-17.8</td>
<td>8</td>
<td>I</td>
</tr>
<tr>
<td>9 months</td>
<td>53</td>
<td>58</td>
<td>-18.1</td>
<td>3</td>
<td>I</td>
</tr>
<tr>
<td>12 months</td>
<td>53</td>
<td>55</td>
<td>-17.1</td>
<td>2</td>
<td>I</td>
</tr>
<tr>
<td>24 months</td>
<td>52</td>
<td>54</td>
<td>-17.9</td>
<td>-</td>
<td>I</td>
</tr>
</tbody>
</table>
**Figure 1:** CMR tools to understand the underlying mechanisms of cardiotoxicity. (Panels A and B) Cardiac MRI studies in a patient during and after 6-month withdrawal of trastuzumab: end-diastolic (EDV) frame, end-systolic (ESV) frame, feature tracking analysis and curves and native T1 mapping. At 6-month withdrawal, both EDV and ESV are reduced, ejection fraction increased, longitudinal strain improved, and native T1 values were reduced. This case demonstrated the reversible nature of trastuzumab cardiomyopathy. (Panel C) CMR study in a patient with anthracycline-cardiomyopathy, with reduced EDV and ESV, reduced ejection, impaired global longitudinal strain, and presence of subepicardial and mid-wall late gadolinium enhancement (LGE) in the septum, inferior and inferolateral walls.
Figure 2: Myocarditis identified by cardiac MRI. Panel A demonstrates a focal area of myocardial edema on spectral attenuated inversion recovery (SPAIR) image (arrow) while panel B demonstrated sub-epicardial enhancement (arrow) on late gadolinium enhancement images reflective of myocardial cell death. The sub-epicardial enhancement is a pattern often seen in myocarditis.
Figure 3: Assessment of pericardial constriction using cardiac MRI. Panel A demonstrates a T1 weighted spin echo sequence demonstrating thickening of the pericardium (arrow). Panel B and C demonstrate a real time cine sequence with normal position of the interventricular septum in expiration (Panel B), but shift into the LV during inspiration (Panel C). This finding of respirophasic septal shift is a hemodynamic feature of constrictive physiology.
Figure 4: Cardiac computed tomography for assessment of coronary artery disease. In patients with prior chest radiation Panel A demonstrates pericardial calcification, panel B significant proximal coronary artery disease involving the left anterior descending. Panel C demonstrates mixed plaque in proximal LAD in a patient experience chest pain during treatment with 5-fluorouracil.
Figure #5: Significant peri-infarct ischemia (panel A, white arrow) in the basal to mid-cavity of the anterior wall (LAD territory) in a 57 year old male with a prior history of chemotherapy and radiation for small cell lung cancer.

Panel A: Basal, mid, apical short-axis slice first pass perfusion images using a GRE sequence after adenosine infusion and administration of 0.1 mmol / kg of gadolinium chelate contrast agent. Panel B: corresponding basal, mid, apical short-axis late gadolinium enhancement images using a IR-GRE sequence 15-20min after contrast administration.